Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

NCT06323382 · clinicaltrials.gov ↗

RECRUITING

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma
Anti-PD1/PDL1 Antibody
Bevacizumab

Interventions

PROCEDURE: Locoregional therapy
DRUG: Bevacizumab
DRUG: Atezolizumab
DRUG: Tislelizumab
DRUG: Toripalimab
DRUG: Sintilimab
DRUG: Camrelizumab

Sponsor

Sun Yat-sen University